This research reveals selective PARP1 inhibitors improve cancer treatment outcomes in tumors with homologous recombination deficiencies, indicating their potential in precision medicine.
Poly(ADP-ribose) polymerase 1 (PARP1) is a critical enzyme involved in the DNA damage response. The therapeutic inhibition of PARP1 has emerged as a promising strategy, particularly in cancers with homologous recombination deficiencies (HRDs). A recent report disclosed the discovery of (S)-G9 as a selective PARP1 inhibitor for clinical development.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: